Parmax Pharma Ltd - 540359 - Corrigendum To The Notice Of (2Nd/2026-27) Extraordinary General Meeting Of The Company
Parmax Pharma announced a corrigendum to its EGM notice, reclassifying several warrant allottees to the Promoter/Promoter Group. This change triggers SEBI SAST regulations, mandating an open offer process, and is expected to consolidate promoter control.
Jun 23 2026 19:26:12
Parmax Pharma Ltd - 540359 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Pradeep Gosalia disposed of 300,000 equity shares of Parmax Pharma, decreasing his holding from 8.09% to 0.07%. The transaction was executed on June 18, 2026, via an off-market share purchase agreement.
Jun 23 2026 11:25:40
Parmax Pharma Ltd - 540359 - Disclosures under Reg. 18(6) of SEBI (SAST) Regulations, 2011
Abhay Chinubhai Shah (PAC 8) acquired 2,49,394 equity shares of Parmax Pharma Ltd through an off-market transaction on June 18, 2026. This acquisition increased the total shareholding of the acquirer and PAC group from 20.54% to 27.20%, marking a significant 6.66% stake hike. The transaction was valued at Rs.87.29 lakh.
Jun 19 2026 15:13:21
Parmax Pharma Ltd - 540359 - Disclosures under Reg. 18(6) of SEBI (SAST) Regulations, 2011
Rupa Sunil Shah, part of Parmax Pharma's promoter group (PAC 5), acquired 53,520 equity shares on June 16, 2026, via an off-market transaction at Rs.35.00 per share. This transaction increases her individual holding to 1.43% and the overall acquirer group's stake to 20.54%.
Jun 17 2026 19:37:30
Parmax Pharma Ltd - 540359 - Detailed Public Statement
Acquirers Dhiren Chandulal Shah and Sunil Chinubhai Shah, along with Persons Acting in Concert (PACs), have launched an open offer to acquire 26.00% of Parmax Pharma's expanded voting share capital from public shareholders. This involves 23.46 lakh equity shares.
Jun 15 2026 18:34:27
Parmax Pharma Ltd - 540359 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Parmax Pharma will hold its 2nd Extra Ordinary General Meeting on July 09, 2026. Key agendas include seeking shareholder approval to significantly increase the company's borrowing limit from Rs.25 crore to Rs.100 crore, as well as approving the re-appointment of Mr. Umang Alkeseh Gosalia as MD and the appointments of Mr. Vijay Babulal Prajapati and Mrs. Reema Umang Gosalia as Whole-time Directors.
Jun 11 2026 19:24:34
Parmax Pharma Ltd - 540359 - EGM Scheduled To Be Held On July 02, 2026
Parmax Pharma is seeking shareholder approval to raise ₹19.28 crore through a preferential issue of 3.13 million equity shares and 2.14 million convertible warrants at ₹36.50 each. This fundraise will lead to a change in promoter control and trigger a mandatory open offer.
Jun 09 2026 23:02:55
Parmax Pharma Ltd - 540359 - Announcement under Regulation 30 (LODR)-Memorandum of Understanding /Agreements
A new investor group is set to acquire majority control of Parmax Pharma through a combination of a Share Purchase Agreement and a preferential allotment totaling Rs.19.28 crore. The board will be reconstituted post-transaction.
Jun 09 2026 22:51:40
Parmax Pharma Ltd - 540359 - Open Offer
An open offer for Parmax Pharma has been announced to acquire up to 26% of its expanded voting capital. The offer price is ₹42.80 per share, with a total consideration of up to ₹10.04 crore by Dhiren & Sunil Shah along with PACs, signaling a change in control.
Jun 09 2026 08:51:23
Parmax Pharma Ltd - 540359 - Board Meeting Outcome for Outcome Of Board Meeting
Parmax Pharma's board approved a ₹19.28 crore preferential issue to non-promoter group allottees, increasing authorized capital to ₹1000 crore. An EGM on July 2, 2026, will seek shareholder approval for this fundraise, new Articles of Association, and the related change in company control.
Jun 08 2026 15:22:46
Read More